- Home
- AGAE vs SPRO Comparison
AGAE vs SPRO Comparison
Compare AGAE & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- SPRO
- Stock Information
- Founded
- AGAE 2017
- SPRO 2013
- Country
- AGAE United States
- SPRO United States
- Employees
- AGAE N/A
- SPRO N/A
- Industry
- AGAE Cable & Other Pay Television Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- SPRO Health Care
- Exchange
- AGAE Nasdaq
- SPRO Nasdaq
- Market Cap
- AGAE 47.2M
- SPRO 45.7M
- IPO Year
- AGAE N/A
- SPRO 2017
- Fundamental
- Price
- AGAE $1.02
- SPRO $0.69
- Analyst Decision
- AGAE
- SPRO Buy
- Analyst Count
- AGAE 0
- SPRO 4
- Target Price
- AGAE N/A
- SPRO $5.00
- AVG Volume (30 Days)
- AGAE 19.9K
- SPRO 121.5K
- Earning Date
- AGAE 05-19-2025
- SPRO 03-27-2025
- Dividend Yield
- AGAE N/A
- SPRO N/A
- EPS Growth
- AGAE N/A
- SPRO N/A
- EPS
- AGAE N/A
- SPRO N/A
- Revenue
- AGAE $9,256,023.00
- SPRO $47,977,000.00
- Revenue This Year
- AGAE N/A
- SPRO N/A
- Revenue Next Year
- AGAE N/A
- SPRO N/A
- P/E Ratio
- AGAE N/A
- SPRO N/A
- Revenue Growth
- AGAE 36.15
- SPRO N/A
- 52 Week Low
- AGAE $0.61
- SPRO $0.68
- 52 Week High
- AGAE $1.57
- SPRO $1.81
- Technical
- Relative Strength Index (RSI)
- AGAE 43.33
- SPRO 35.60
- Support Level
- AGAE $1.08
- SPRO $0.75
- Resistance Level
- AGAE $1.11
- SPRO $0.80
- Average True Range (ATR)
- AGAE 0.05
- SPRO 0.05
- MACD
- AGAE -0.01
- SPRO -0.01
- Stochastic Oscillator
- AGAE 40.00
- SPRO 5.83
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.